Latin America is a critical region for generic pharmaceutical manufacturers. Institutional regulators, organised public procurement and large patient populations make LATAM a strategic market - with distinct entry considerations.
1. Key Regulators #
| Country | Regulator |
|---|---|
| Brazil | ANVISA |
| Mexico | COFEPRIS |
| Colombia | INVIMA |
| Peru | DIGEMID |
| Argentina | ANMAT |
| Chile | ISP |
| Ecuador | ARCSA |
2. Dossier Expectations #
LATAM regulators typically expect:
- Full CTD dossier (Module 1-5)
- Bioequivalence vs reference product (where applicable)
- Module 1 localised to Spanish or Portuguese (Brazil)
- Stability data per applicable climatic zone (IVa typical)
- CoPP on WHO format
- Legal / apostille documentation per country
3. Typical Registration Timelines #
- Brazil (ANVISA): 12-24 months
- Mexico (COFEPRIS): 18-30 months
- Colombia (INVIMA): 9-18 months
- Peru / Argentina: 12-18 months
4. Market Access After Approval #
- Public-sector procurement through ministries / social-security institutes
- Private pharmacy distribution
- Specialty hospital channels for hematology products
- Institutional pricing negotiations
5. Practical Entry Strategy #
- Start with 1-2 priority countries; avoid spreading too thin
- Partner with experienced local distributor / MAH with RA capability
- Prepare Portuguese and Spanish Module 1 in parallel
- Build pharmacovigilance and QA infrastructure early
- Plan 12-24 month pre-launch marketing in hematology specialty
6. Deferasirox in LATAM #
LATAM has meaningful thalassemia and SCD populations - creating durable demand for oral iron chelation. Taj Pharma supplies DEFRATAJ across the region - see LATAM lander.